Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
24
pubmed:dateCreated
2004-12-29
pubmed:abstractText
Hypoxia plays a critical role in driving tumor malignancy and is associated with poor patient survival in many human cancers. Novel therapies targeting hypoxic tumor cells are urgently needed, because these cells hinder tumor eradication. Here we demonstrate than an anticancer strategy based on intratumoral delivery of a novel type of oncolytic adenovirus targeting tumor hypoxia is therapeutically efficient and can augment standard chemotherapy. We used a conditionally replicative adenovirus (HYPR-Ad) to specifically kill hypoxic tumor cells. Viral infection and conditional replication occurred efficiently in hypoxic/hypoxia-inducible factor-active cells in culture and in vivo, prevented tumor formation, and reduced the growth of established tumors. Combining HYPR-Ad with chemotherapy effective against normoxic cells resulted in strongly enhanced antitumor efficacy. These studies demonstrate that targeting the hypoxic microenvironment of tumors rather than an intrinsic gene expression defect is a viable and novel antitumor therapeutic strategy that can be used in combination with existing treatment regimens. The replication and oncolytic potential of this virus was made dependent on hypoxic/hypoxia-inducible factor, a transcription factor activated in the tumor hypoxic microenvironment, broadening its therapeutic use to solid tumors of any genetic make-up or tissue of origin.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
8603-12
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:15623644-Adenoviridae, pubmed-meshheading:15623644-Adenovirus E1A Proteins, pubmed-meshheading:15623644-Animals, pubmed-meshheading:15623644-Antineoplastic Agents, Alkylating, pubmed-meshheading:15623644-Brain Neoplasms, pubmed-meshheading:15623644-Carmustine, pubmed-meshheading:15623644-Cell Hypoxia, pubmed-meshheading:15623644-Combined Modality Therapy, pubmed-meshheading:15623644-DNA-Binding Proteins, pubmed-meshheading:15623644-Glioma, pubmed-meshheading:15623644-Humans, pubmed-meshheading:15623644-Hypoxia-Inducible Factor 1, pubmed-meshheading:15623644-Hypoxia-Inducible Factor 1, alpha Subunit, pubmed-meshheading:15623644-Mice, pubmed-meshheading:15623644-Mice, Nude, pubmed-meshheading:15623644-Nuclear Proteins, pubmed-meshheading:15623644-Transcription Factors, pubmed-meshheading:15623644-Tumor Cells, Cultured, pubmed-meshheading:15623644-Virus Replication, pubmed-meshheading:15623644-Xenograft Model Antitumor Assays
pubmed:year
2004
pubmed:articleTitle
Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors.
pubmed:affiliation
Laboratory of Molecular Neuro-Oncology, Department of Neurosurgery, Emory University, Atlanta, Georgia 30322, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, N.I.H., Extramural